Trial Profile

A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of a Single Intravenous (IV) Infusion of TRP-8803 (psilocin) in Healthy Adult Participants

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 12 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Psilocybin (Primary)
Indications Binge-eating disorder; Cancer; Complex regional pain syndromes; Fibromyalgia; Pain
Focus Adverse reactions

12 Jan 2024 New trial record
08 Jan 2024 According to a TRYP Therapeutics media release, achieving the three predetermined targets of psilocin blood levels in this study and confirming their safety will serve as the basis for dose selection in our planned Phase 2 studies with TRP-8803.
08 Jan 2024 According to a TRYP Therapeutics media release, The Company has received approval from the Human Research Ethics Committee (HREC) in Australia to commence the groundbreaking Phase 1 clinical trial of TRP-8803 in healthy human volunteers.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com